REG - Hikma Pharmaceutical - Result of AGM

Hikma PharmaceuticalsAnnouncement

23/04/2021 15:55

RNS Number : 4938W
  
Hikma Pharmaceuticals Plc
  
23 April 2021
  
 

 
Hikma Pharmaceuticals PLC 
Voting Results of 2021 Annual General Meeting
LONDON, 23 April 2021  Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) announces its Annual General Meeting ("AGM"), held at 1 New Burlington Place, W1S 2HR, London on 23 April 2021 commenced at 1:00 pm. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 15 and 17 were passed as ordinary resolutions and Resolutions 16 and 18 to 22 were passed as special resolutions. 
Copies of the resolutions dealing with special business passed at the AGM have been submitted to the to the FCA's Electronic Submission System and will be available from the National Storage Mechanism.
The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 24 February 2021) is set out below. The number of Ordinary Shares in issue on 23 April 2021 was 243,604,637.  There were 12,833,233 Ordinary Shares held in treasury, which are not counted in the voting capital of the Company which, therefore, was 230,771,404.




Resolution


Votes For


%


Votes Against


%


Total Cast


Withheld





1. To receive the 2020 report and accounts


176,723,133


100.0


16,692


0


176,739,825


1,537,096




2. To approve a final dividend of 34 cents per share


178,275,824


100.0


152


0


178,275,976


945




3. To re-appoint PricewaterhouseCoopers LLP as auditors


177,053,202


99.3


1,222,474


0.7


178,275,676


1,245




4.To authorise the Audit Committee to determine the auditors' remuneration 


178,174,755


99.9


100,365


0.1


178,275,120


1,801




5. To elect Douglas Hurt as a director


174,859,594


98.1


3,414,131


1.9


178,273,725


3,196




6. To re-elect Said Darwazah as a director


171,553,543


97.2


4,923,908


2.8


176,477,451


1,799,470




7. To re-elect Siggi Olafsson as a director


176,112,071


98.8


2,163,336


1.2


178,275,407


1,514




8. To re-elect Mazen Darwazah as a director


171,246,066


96.1


6,949,669


3.9


178,195,735


81,186




9. To re-elect Patrick Butler as a director


172,831,258


97.0


5,434,621


3.1


178,265,879


11,041




10.To re-elect Ali Al-Husry as a director


175,142,703


98.3


3,053,032


1.7


178,195,735


81,186




11. To re-elect Dr. Pamela Kirby as a director


167,790,753


95.1


8,655,778


4.9


176,446,531


1,830,390




12. To re-elect John Castellani as a director


175,101,327


98.9


1,975,760


1.1


177,077,087


1,199,834




13. To re-elect Nina Henderson as a director


175,403,863


98.4


2,871,070


1.6


178,274,933


1,988




14. To re-elect Cynthia Schwalm as a director


154,099,252


86.5


24,120,681


13.5


178,219,933


56,988




15. To approve the remuneration report for the year ended 31 December 2020


160,014,990


90.4


17,063,364


9.6


177,078,354


1,198,566




16. To approve the adoption of the new articles of association for the Company


177,680,870


99.7


593,294


0.3


178,274,164


2,757




17. Authority to allot shares


154,848,864


86.9


23,426,822


13.1


178,275,686


1,235




18. To dis-apply pre-emption rights for general purposes


177,563,944


99.6


711,824


0.4


178,275,768


1,153




19. To dis-apply pre-emption rights for an acquisition or other capital investment


174,606,709


97.9


3,668,585


2.1


178,275,294


1,627




20. To authorise the Company to purchase its own shares


176,712,127


99.2


1,480,842


0.8


178,192,969


83,952




21. To authorise the Company to hold general meetings on no less than 14 clear days' notice


169,544,820


95.1


8,731,027


4.9


178,275,847


1,074



 
Declaration of final dividend
The dividend of 34 cents per share will be paid on 26 April 2021 to shareholders on the register on 19 March 2021.  Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling.  The exchange rate in respect of this dividend will be $1.3762998 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa $1 to 0.709JD.
- ENDS -
Enquiries:
 



Hikma Pharmaceuticals PLC


 




Peter Speirs
Company Secretary
 


+44 20 7399 2670




Susan Ringdal
EVP, Strategic Planning and Global Affairs
 


+44 20 7399 2670
 



 
 
 
 
About Hikma
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com.
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
RAGSEUFLDEFSEDL